Amneal Pharmaceuticals (AMRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Critical company metrics and information
Share Price
$8.53Market Cap
$2.64 BillionTotal Outstanding Shares
309.84 Million SharesTotal Employees
7,700Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.amneal.com
Historical Stock Splits
If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution Date | Split Amount |
---|---|
August 26, 2013 | 1-for-25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-78.63 Million |
Exchange Gains/Losses | $58000.00 |
Net Cash Flow From Financing Activities | $-251.42 Million |
Net Cash Flow, Continuing | $-17.20 Million |
Net Cash Flow From Operating Activities, Continuing | $312.84 Million |
Net Cash Flow From Operating Activities | $312.84 Million |
Net Cash Flow From Investing Activities | $-78.63 Million |
Net Cash Flow From Financing Activities, Continuing | $-251.42 Million |
Net Cash Flow | $-17.26 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $23.32 Million |
Basic Earnings Per Share | $0.86 |
Research and Development | $182.53 Million |
Operating Expenses | $759.67 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-184.45 Million |
Diluted Average Shares | $328.54 Million |
Benefits Costs and Expenses | $2.80 Billion |
Operating Income/Loss | $187.73 Million |
Other Operating Expenses | $120.38 Million |
Costs And Expenses | $2.80 Billion |
Income/Loss From Continuing Operations After Tax | $-146.48 Million |
Net Income/Loss | $-146.48 Million |
Basic Average Shares | $331.46 Million |
Income/Loss From Continuing Operations Before Tax | $-123.16 Million |
Net Income/Loss Attributable To Parent | $-179.73 Million |
Revenues | $2.68 Billion |
Preferred Stock Dividends And Other Adjustments | $4.73 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $4.73 Million |
Cost Of Revenue | $1.73 Billion |
Nonoperating Income/Loss | $-310.88 Million |
Selling, General, and Administrative Expenses | $456.75 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $37.98 Million |
Diluted Earnings Per Share | $0.85 |
Gross Profit | $947.39 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $1.95 Billion |
Other Current Liabilities | $795.31 Million |
Current Assets | $1.51 Billion |
Other Non-current Liabilities | $5.15 Million |
Wages | $64.90 Million |
Intangible Assets | $780.19 Million |
Long-term Debt | $2.39 Billion |
Equity Attributable To Noncontrolling Interest | $135000.00 |
Liabilities | $3.49 Billion |
Equity | $-93.57 Million |
Other Non-current Assets | $736.48 Million |
Assets | $3.46 Billion |
Current Liabilities | $1.10 Billion |
Temporary Equity | $59.89 Million |
Accounts Payable | $235.00 Million |
Liabilities And Equity | $3.46 Billion |
Inventory | $596.36 Million |
Equity Attributable To Parent | $-93.43 Million |
Noncurrent Liabilities | $2.40 Billion |
Fixed Assets | $431.02 Million |
Other Current Assets | $916.93 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.